10421 Pacific Center Court
About AnaptysBio, Inc.
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, our proprietary anti-interleukin-33 antibody, for the treatment of atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps.
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Stock Exchange: NASDAQ
Stock Symbol: ANAB
92 articles with AnaptysBio, Inc.
AnaptysBio, Inc. Expands Patent Portfolio with Issuance of U.S. Patent to in Vitro Somatic Hypermutation
AnaptysBio, Inc. Describes Technology for the Discovery and Optimization of Fully Human Antibodies in Original Research Publication
AnaptysBio, Inc. Appoints Carol G. Gallagher as Executive Chair and Promotes Senior Leaders Hamza Suria and David J. King
Defense Advanced Research Projects Agency Extends Contract with AnaptysBio, Inc. to Generate Additional High Affinity Thermally Stable Antibodies
AnaptysBio, Inc. Successfully Generates Therapeutic Antibodies in Partnership with a Leading Global Pharma
AnaptysBio, Inc. Receives Milestone Payment from Merck & Co., Inc. for Successful Delivery of Candidate Antibodies for Therapeutic Use
AnaptysBio, Inc. Begins Receiving Funds from Qualifying Therapeutic Discovery Project Awards Totaling $860,482
AnaptysBio, Inc. Adds Dr. Jan de Vries, Dr. Nicholas Lydon and Dr. Phillip Patten to Advisory Boards
AnaptysBio, Inc. Expands Global Leadership in Somatic Hypermutation for Antibody Discovery and Optimization with Newly Issued Patents